BofA warns Fed risks policy mistake with early rate cuts
John E. Davis, the Chief Commercial Officer of Artivion, Inc. (NYSE:AORT), a nearly $1 billion market cap medical device company, recently executed a series of stock transactions, according to a recent SEC filing. InvestingPro analysis indicates the company maintains a GOOD financial health score of 2.61. On March 6, 2025, Davis sold 2,618 shares of Artivion’s common stock at an average price of $24.80 per share, amounting to a total value of $64,938. This sale was conducted to cover tax withholding obligations related to the vesting of performance stock units. The transaction occurred as the stock’s RSI suggests oversold conditions, with shares trading at $23.50, down about 18% year-to-date.
Additionally, Davis acquired 25,654 shares of common stock on the same day. These shares were part of a performance stock unit grant from February 2024, with one-third of the shares issued on March 6, 2025. The remaining shares are scheduled to vest in February 2026 and February 2027, pending continued employment. Following these transactions, Davis holds 207,968 shares of Artivion directly. While currently unprofitable, InvestingPro data shows analysts expect the company to turn profitable this year, with 8 more exclusive insights available to subscribers.
In other recent news, Artivion Inc. reported its fourth-quarter 2024 earnings, revealing revenue of $97.3 million, which fell short of the forecasted $100.82 million. This shortfall was primarily due to a cybersecurity incident that impacted revenue by approximately $4.5 million. Despite this, Artivion’s adjusted EBITDA for the quarter exceeded expectations at $17.6 million, compared to the anticipated $17 million. The company’s full-year revenue for 2024 totaled $388.5 million, which was below the guidance range of $389 million to $396 million. Looking ahead, Artivion projects 2025 revenue to be between $420 million and $435 million, with adjusted EBITDA expected to reach between $84 million and $91 million.
Analyst firms have responded to these developments with mixed adjustments. Stifel lowered its price target for Artivion to $30 from $33 but maintained a Buy rating, while Needham reduced its price target to $32 from $34, also keeping a Buy rating. JMP Securities, however, maintained its $33 price target and Market Outperform rating, noting that the company’s operational levels have returned to normal after the cybersecurity incident. The incident had affected Artivion’s tissue preservation division, which saw an 8% decline year-over-year, but management expects to recover the revenue lost over the course of 2025. Additionally, Artivion’s product lines such as On-X, stent grafts, and BioGlue reported growth, with On-X seeing a 10% increase in constant currency terms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.